is tirzepatide insulin or non insulin for the treatment of adults with type 2 diabetes: An endocrine perspective - De Block - 2023 - Diabetes, Obesity and Metabolism Tirzepatide for diabetes: on track

Eli Lilly announced positive topline results from the ATTAIN-2 Phase 3 trial of orforglipron, an oral GLP-1 receptor agonist for obesity and type 2 diabetes.

PlexusDx offers personalized tirzepatide options starting at $249/month with genetic insights to help minimize side effects

Learn how this injection works, its benefits, side effects, and whether its right for you.

Innovative GLP-1 medications are set to redefine therapy standards, providing remarkable advantages in glucose regulation and weight management, while also safeguarding vital organs such as the heart and kidneys.

Universal Compatibility: Compatible with most injection pens including Ozempic, Wegovy, Mounjaro, Saxenda, Victoza, and other GLP-1 and pen injector devices

Persistence (time remaining on treatment) was assessed with KaplanMeier survival estimates and Cox proportional hazard models